ArticleHeliyon2023
FIR-preconditioning promotes Akt-mTOR-exosome manufacture in cooperation with MITF to boost resilience of rat bone marrow-derived stem cells.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Low-molecular-weight fucoidan inhibits the proliferation of melanoma via Bcl-2 phosphorylation and PTEN/AKT pathway.Oncology research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A previous study from our laboratory observed the protective effects of far-infrared irradiation (FIR) on bone marrow-derived stem cells (BMSCs) against oxidative stress. However, it remains unknown precisely how FIR influences BMSC survival. We identify an unexpected route among the expression of MITF, BCL2, mTOR, and exosome in FIR-preconditioned BMSCs. MITF siRNA demonstrated that loss of MITF expression not only inhibited cell proliferation but also reduced the FIR-mediated expression of mTOR, BCL2, and exosome. mTOR signaling pathways have been implicated in cell growth, proliferation, and survival. We also found that rapamycin, a potent and selective inhibitor of mTOR, when combined with MITF siRNA, repressed FIR-mediated CD63 and BCL2 expression. In addition, FIR-preconditioned BMSCs demonstrated more tolerance in multiple stressful environments than untreated BMSCs. The elevated exosomes in conditioned medium derived from FIR-preconditioned BMSCs also repaired H9c2 cells that sustained cellular damage after subjected to an array of environmental stress conditions. Taken together, these results reveal a possible mechanism about how FIR-preconditioned BMSCs and its conditioned media could contribute to cellular resilience during environmental changes via MITF-Akt-mTOR associated with exosome manufacture. FIR preconditioning could thus complement and improve therapeutic applications of BMSCs on outcomes of various disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.